Preventive and Therapeutic Vaccine Market Size, Industry Analysis Report, Regional Outlook, Application Growth Potential, Competitive Market Growth & Forecast, 2025 – 2034
Report ID: GMI1645
Download Free PDF
Authors:
Monali Tayade,
Preventive and Therapeutic Vaccine Market Size
The global preventive and therapeutic vaccine market garnered sizeable revenues in 2024 and is forecasted to grow at a moderate CAGR through 2025 - 2034, due to the increasing global burden of infectious and chronic diseases. As per the CDC, six out of ten Americans lived with at least one chronic disease, and four out of ten had two or more chronic conditions. Greater expansion of immunization programs and increased investment in biotechnology and vaccine research will also add some propulsion.
Preventive vaccines have always served as the foundation of global immunization, and they have been extremely effective in reducing both morbidity and mortality in diseases such as polio, measles, hepatitis, and influenza. Therapeutic vaccines are also emerging, particularly in cancer, autoimmune diseases, and chronic infections like HIV. A growing elderly population, increasing focus on preventing illness, and so on, raise the demand for new vaccine technologies and for broad-spectrum vaccines. With both governments and private institutions continuing to invest in improving public health through vaccination programs, there is a moderate growth in this market.
Furthermore, there is a growing emphasis on therapeutic vaccines, which provide treatment alternatives, especially in oncology (where vaccine-based strategies enhance the immune system response as opposed to primary or secondary vaccinations against pathogens). However, some issues persist in this market, with aspects such as vaccine hesitancy existing within world regions, ever-escalating costs of development, complex regulatory pathway processes, and cold chain logistics. Moreover, the investment in R&D, combined with lengthy timelines for trials assessing safety and efficacy, may also hinder product commercialization. In addition, access issues to vaccines in low-income and rural-urban areas detract from global aims towards universal vaccination.
Preventive and Therapeutic Vaccine Market Trends
The vaccine market is undergoing rapid change as both the preventive and therapeutic segments merge in response to new scientific advances, new health priorities, and the COVID-19 pandemic. One prominent trend contributing to growth is the observed shift towards personalized and precision medicine in the development of vaccines, especially about cancers and autoimmune diseases. This shift towards therapeutics has gained momentum in part due to increased understanding of genomics and immunotherapy, and the application of cancer vaccines targeting specific tumor antigens.
Another apparent trend is the extension of vaccine portfolios for non-infectious disease therapy targeting existing, unmet medical needs. For example, researchers are conducting exploratory studies on the potential of therapeutic vaccines to treat diseases such as Alzheimer's, asthma, and multiple sclerosis, simply because the innovative opportunity exists. One last trend is the push toward using artificial intelligence and machine learning to expedite the identification of vaccine candidates and trial procedures. In summary, the combined move toward innovation and accessibility, combined with a focus on adaptability within both the therapeutic and preventive vaccine segments, is altering the landscape for the vaccine industry, providing opportunities for different players.
Preventive and Therapeutic Vaccine Market Analysis
The preventive vaccines segment held a significant share in 2024. Preventive vaccines are the first line of defense against infectious disease, providing long-lasting immunity and reducing pathogen transmission within populations. Their proven effectiveness, combined with global inclusion into National Immunization Programs, helps to solidify their position as one of the cornerstones of public health strategy. Vaccines for influenza, human papillomavirus (HPV), rotavirus, and hepatitis B have become part of routine prevention across the life course and have greatly reduced disease burden. Demand for preventive vaccines is further endorsed by increasing attention, studies, and investment in universal immunization efforts by global organizations like GAVI, WHO, and UNICEF.
Preventive vaccines have a lower cost, broad applicability, and established public health delivery. More importantly, preventive vaccines are also being utilized more frequently for public health travel medicine and newly emerging infectious diseases, particularly in countries that are identified as outbreak vulnerable. While therapeutic vaccines present a growing opportunity and potential platform for disease areas like oncology, preventive vaccines will continue to be the dominant category due to their lower cost, broader applicability, and where immunization programs exist.
The conjugate vaccines segment accounted for a substantial share in 2024. These vaccines are made by binding antigens or toxoids from a microbe with carrier proteins to enhance an immune response, particularly in infants and older adults. Conjugate vaccines demonstrate robust protection against bacteria that are encapsulated by a polysaccharide outer coating. Some examples of bacteria with polysaccharide coats are Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis.
It has contributed to increasingly low rates of severe bacterial infections such as meningitis and pneumonia. The chief driver of growth for conjugate vaccines is the growing global and national emphasis on childhood immunizations through national governments and the World Health Organization. In addition, more developer combination conjugate vaccines that safeguard against serotypes are also promoting the uptake of combination vaccines. Moreover, the study to improve conjugate vaccines against these emerging pathogens is opening new growth opportunities in the market.
North America preventive and therapeutic vaccine market accounted for the largest share in 2024, driven by the region's well-developed healthcare system, vaccination coverage and regulatory systems, government support for vaccines, and an overall heavy investment in public vaccination programs. The United States, with major investments in biomedical research and investment in public health preparedness, has become a significant global participant in vaccine research and development, as well as vaccine distribution and immunization programs.
Notably, the COVID-19 rollout in North America showed the region's ability to navigate mass immunization campaigns and demonstrated its overall public health capacity for expanding immunization coverage. Pharmaceutical and biotech companies in North America are leading innovators in the vaccine industry and introduce new vaccine platforms (e.g., mRNA, viral vectors, and adjuvanted vaccines) frequently. The regulatory apparatus set up by federal organizations like the FDA and Health Canada can help to speed approval and support the distribution of new vaccines.
Preventive and Therapeutic Vaccine Market Share
Major companies in the preventive and therapeutic vaccine industry include:
To solidify their place in the preventive and therapeutic vaccine market, companies are adopting a variety of strategies. One major strategy has been a significant investment in R&D to innovate new vaccine platforms using mRNA and vector technologies. Many of these top players are also entering into strategic collaborations or licensing agreements with biotech companies and universities to develop products and diversify their pipeline. They have also been significantly expanding geographies through agreements with governments and global health organizations to get more vaccines into challenging populations.
Some companies have been improving production capability, including establishing local production units to meet regional demands. Additionally, mergers and acquisitions are being used to secure company positions and gain access to new vaccine candidates. Altogether, this portfolio of strategies allows companies to rapidly respond to emerging health threats and gain a competitive advantage in an ever-changing landscape.
Preventive and Therapeutic Vaccine Industry News
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →